Results 81 to 90 of about 116,907 (303)

Nintedanib-Induced Renal Thrombotic Microangiopathy

Case Reports in Nephrology and Dialysis, 2021
Nintedanib is a unique tyrosine kinase inhibitor used to suppress fibrosis in patients with idiopathic pulmonary fibrosis (IPF). Nintedanib has been shown to suppress multiple processes of fibrosis, thereby reducing the rate of lung function decline in ...
Takeshi Fujita, Hideyuki Nakagawa, Takashi Yokota, Jun Umetani, Daiki Nagawa, Masamichi Nakata, Ikuyo Narita-Kinjo, Reiichi Murakami, Michiko Shimada, Norio Nakamura, Hirofumi Tomita   +10 more
doaj   +1 more source

Post‐COVID‐19 condition: clinical phenotypes, pathophysiological mechanisms, pathology, and management strategies

The Journal of Pathology, EarlyView.
Abstract Post‐COVID‐19 condition (PCC), also known as long COVID, is a complex multiple organ system condition that can develop and persist for months after acute COVID‐19. PCC encompasses a wide range of symptoms, resulting in heterogeneous clinical manifestations. These manifestations likely arise from diverse underlying pathophysiological mechanisms,
Larissa E Vlaming‐van Eijk, Guolu Tang, Arno R Bourgonje, Wilfred F A den Dunnen, Jan‐Luuk Hillebrands, Harry van Goor   +5 more
wiley   +1 more source

Thrombotic Microangiopathy in the Setting of Colorectal Cancer: A Therapeutic Challenge with a Bad Prognosis

Hematology Reports, 2023
While most cases of thrombotic microangiopathic hemolytic anemias are idiopathic, some can occur in the setting of a malignancy. Differentiating both conditions is crucial to initiate the appropriate treatment.
Youssef Bouferraa, Yolla Haibe, Hanan Hamdan, Rami Mahfouz, Zaher Chakhachiro, Ali Shamseddine   +5 more
doaj   +1 more source

Quantitative Systems Pharmacology Modeling of Platelet Responses to Recombinant ADAMTS13 in Patients With Congenital Thrombotic Thrombocytopenic Purpura

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra‐rare, life‐threatening thrombotic microangiopathy caused by a severe inherited deficiency of ADAMTS13, a von Willebrand factor (VWF) cleaving enzyme. Inadequate clinical endpoint data often make it challenging to statistically power clinical trials in ultra‐rare diseases ...
Cameron McBride, Jiaolong Jiang, Zhiwei Zhang, John Tolsma, Parth Patwari, Björn Mellgård, Majid Vakilynejad, Indranil Bhattacharya, Andy Z. X. Zhu   +8 more
wiley   +1 more source

Safety and efficacy of eculizumab in adult and pediatric patients with aHUS, with or without baseline dialysis [PDF]

, 2015
C
Hourmant, Maryvonne, Kincaid, John F, Legendre, Christophe M, Menne, Jan, van de Kar, Nicole CAJ, Vande Walle, Johan   +5 more
core   +1 more source

Thrombotic microangiopathy and associated renal disorders [PDF]

, 2012
Thrombotic microangiopathy (TMA) is a pathological process involving thrombocytopenia, microangiopathic haemolytic anaemia and microvascular occlusion.
Barbour, T, Cohney, S, Hughes, P, Johnson, S   +3 more
core   +1 more source

Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy

Journal of Clinical Immunology, 2020
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of excessive immune system activation driven mainly by high levels of interferon gamma. The clinical presentation of HLH can have considerable overlap with other inflammatory conditions. We present a
N. Gloude, C. Dandoy, S. Davies, K. Myers, M. Jordan, R. Marsh, Ashish R. Kumar, J. Bleesing, Ashley Teusink‐Cross, S. Jodele   +9 more
semanticscholar   +1 more source

Predictors of systemic sclerosis patients with interstitial lung disease progression: A retrospective study

Rheumatology &Autoimmunity, EarlyView.
The final systemic sclerosis patients with interstitial lung disease (SSc‐ILD) progression prediction model was composed of 6 significant risk factors: male, type 2 diabetes mellitus, pericardial effusion, anti‐Ro52, hypoproteinemia, and elevated C‐reactive protein. Our model demonstrated excellent prognostic utility.
Xi Cao, Shanshan Wang, Wenyi Yuan, Mian Liu, Xiaoyan Xin, Xiang Fang, Dandan Wang   +6 more
wiley   +1 more source

Use of the complement inhibitor Coversin to treat HSCT-associated TMA [PDF]

, 2017
Finding an inherited complement abnormality in HSCT-associated TMA provides a rationale for the use of a complement inhibitor.Alternative complement inhibitors such as Coversin should be considered in patients who are resistant to ...
Amrolia, P, Chiesa, R, Goodship, THJ, Machin, SJ, Mackie, I, Nishimura, J-I, Nunn, MA, Palm, L, Pinto, F, Pryce, JW, Silva, J, Veys, P, Weston-Davies, WH   +12 more
core   +1 more source

Thrombotic microangiopathies: An illustrated review

Research and Practice in Thrombosis and Haemostasis, 2022
The thrombotic microangiopathies (TMAs) are a heterogenous group of disorders with distinct pathophysiologies that cause occlusive microvascular or macrovascular thrombosis, and are characterized by microangiopathic hemolytic anemia, thrombocytopenia, and/or end-organ ischemia.
Mouhamed Yazan Abou‐Ismail, Sargam Kapoor, Divyaswathi Citla Sridhar, Lalitha Nayak, Sanjay Ahuja   +4 more
openaire   +3 more sources